Public Policy Committee

BioNJ’s Public Policy Committee serves as an important sounding board for BioNJ’s public policy efforts. The committee is comprised of executive and policy leadership in New Jersey’s life sciences innovation sector, from CEOs to government relations personnel and others. The committee meets regularly to provide BioNJ with feedback on policy machinations in Trenton and beyond; while participating in monthly update calls with BioNJ staff. Committee members frequently hear from guest speakers, including legislators, administrative and regulatory leaders, and others in the life sciences community at committee meetings, events and receptions.

Committee Members

Adastra Pharmaceuticals, Inc. – Scott Megaffin, CEO
Amgen, Inc. – Andrew Marocco, Director, State Government Affairs
Amicus Therapeutics, Inc. – Paul Howard, Director, Public Policy
AzurRx BioPharma – James Sapirstein, MBA, RPh, President and CEO
Bristol-Myers Squibb Company – Ethan Hasbrouck, MPA, State Government Affairs
Consynance Therapeutics – John Maki, President
Eli Lilly & Company – Timothy Lyden, Director, State Government and Business Affairs
Ferring Pharmaceuticals, Inc. – Ed Trott, Chief Patient Officer
Ferring Pharmaceuticals, Inc. – Joseph Zimmerman, Vice President – Chief Compliance & Privacy Officer, U.S.
GlaxoSmithKline –Paul Madrazo, Director, State Government Affairs
GSK Consumer Healthcare – Elizabeth Brewer, MS, MPH, EMBA, Global Lead, Americas – Government Affairs, Public Policy & Advocacy
GSK Consumer Healthcare – Deana Lykins, JD, Lead, Government Affairs – North America
Ipsen US – Bob Feeney, MBA, Vice President, NA Government Affairs and Public Policy
Ipsen US – Francis Rienzo, Head, State Government Affairs & Policy
J&J – Chris Guiton, JD, Senior Director, US State Government Affairs
LEO Pharma Inc. – Manan Shah, Vice President & Head, Global Public Affairs
Merck & Co., Inc. – Domenick Argento, Associate Director, Account Management, Government Affairs & Policy
Novartis Pharmaceuticals – Candie Phipps, Director, State Government and Business Affairs
Novo Nordisk – Brian Kelly, JD, Director, State Government Affairs
OncoSec Medical Inc. – Daniel O’Connor, JD, CEO
OncoSTING – Ambaw Bellete, President and Chair of Public Policy Committee
Otsuka America Pharmaceutical – Judy Jenkins, Associate Director of Advocacy and Policy
Pfizer, Inc. – Wendy Lazarus, Director, U.S. Government Relations
PTC Therapeutics, Inc. – Theodore Piper, Associate Director, State Government Affairs
Rigby Consulting, LLC – Kevin Rigby, JD, Principal
Sanofi – George Coutros, Director, State Government Affairs
Soligenix, Inc. – Dennis Ondrejik, Program Manager
Translatum Medicus, Inc. – Paul Howes MBA, Executive Vice President
Tyme Technologies, Inc. – Michele Korfin, R.Ph.,  MBA, Chief Operating Officer